Vancomycin Hydrochloride for Injection Product Launches

Article

The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.

Officials with Xellia Pharmaceuticals (‘Xellia’) announced they have launched Vancomycin Hydrochloride for Injection, USP within the United States market.

The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.

“Today marks an important milestone for our US market strategy and represents a significant step forward in the company's evolution as we bring the first product to the US market under the Xellia brand,” Carl-Aake Carlsson, Xellia’s CEO, said in a prepared statement about the launch.

Full prescribing information for Vancomycin Hydrochloride for Injection, USP can be found at www.xellia.com/us.

Related Videos
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
Rear view of Audience listening Speakers on the stage in the conference hall or seminar meeting, business and education about investment concept -  Image credit: THANANIT | stock.adobe.com
Pharmacist helping patient use glucose monitor -- Image credit: Kalyakan | stock.adobe.com
Pride flags during pride event -- Image credit: ink drop | stock.adobe.com
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.